Payment overview · 2025
General Payments
$184.85
9 reported records · 7 companies
Healthcare provider profile · identity verified
Everett C Mckibben, MD
Allopathic & Osteopathic Physicians|Family Medicine · STARKVILLE, MS · NPI 1093873713
Verified facts
What the public records show
CMS Open Payments records show Everett C Mckibben, MD received $184.85 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Caplyta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.20 | 45.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.02 | 10.3% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.02 | 9.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.50 | 9.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.89 | 9.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.84 | 8.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.38 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $184.85 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $83.20 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $83.20 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $83.20 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 542 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 528 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 111 |
| Hydrochlorothiazide | Hydrochlorothiazide | 403 | 106 |
| Omeprazole | Omeprazole | 383 | 94 |
| Gabapentin | Gabapentin | 323 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 321 | 78 |
| Furosemide | Furosemide | 312 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 295 | 73 |
| Alprazolam | Alprazolam | 276 | 61 |
| Potassium Chloride | Potassium Chloride | 241 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 238 | 48 |
| Eliquis | Apixaban | 209 | 31 |
| Famotidine | Famotidine | 206 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 51 |
| Losartan Potassium | Losartan Potassium | 197 | 41 |
| Meloxicam | Meloxicam | 196 | 71 |
| Lisinopril | Lisinopril | 193 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 61 |
| Sertraline Hcl | Sertraline Hcl | 171 | 38 |
| Trazodone Hcl | Trazodone Hcl | 148 | 38 |
| Buspirone Hcl | Buspirone Hcl | 141 | 22 |
| Tramadol Hcl | Tramadol Hcl | 137 | 35 |
| Metformin Hcl Er | Metformin Hcl | 131 | 35 |
| Metformin Hcl | Metformin Hcl | 124 | 38 |
| Simvastatin | Simvastatin | 121 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 31 |
| Levetiracetam | Levetiracetam | 115 | 19 |
| Spironolactone | Spironolactone | 106 | 26 |
| Glipizide Er | Glipizide | 105 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 26 |
| Donepezil Hcl | Donepezil Hcl | 96 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 18 |
| Prednisone | Prednisone | 94 | 59 |
| Montelukast Sodium | Montelukast Sodium | 92 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 88 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 30 |
| Carvedilol | Carvedilol | 85 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 83 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 82 | suppressed |
| Januvia | Sitagliptin Phosphate | 82 | suppressed |
| Risperidone | Risperidone | 80 | 13 |
| Allopurinol | Allopurinol | 79 | 23 |
| Xarelto | Rivaroxaban | 75 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 14 |
| Ezetimibe | Ezetimibe | 71 | 21 |
| Glimepiride | Glimepiride | 70 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 18 |
| Synthroid | Levothyroxine Sodium | 69 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 19 |
| Mirtazapine | Mirtazapine | 66 | 18 |
| Temazepam | Temazepam | 66 | suppressed |
| Celecoxib | Celecoxib | 64 | 20 |
| Lorazepam | Lorazepam | 64 | 11 |
| Meclizine Hcl | Meclizine Hcl | 64 | 18 |
| Pregabalin | Pregabalin | 64 | 11 |
| Azithromycin | Azithromycin | 63 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 43 |
| Colchicine | Colchicine | 59 | 12 |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Atenolol | Atenolol | 57 | 16 |
| Methylprednisolone | Methylprednisolone | 57 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 15 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | 11 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Valsartan | Valsartan | 50 | 13 |
| Levofloxacin | Levofloxacin | 49 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 12 |
| Baclofen | Baclofen | 44 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 12 |
| Ozempic | Semaglutide | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 12 |
| Estradiol | Estradiol | 37 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 12 |
| Lactulose | Lactulose | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 27 |
| Bupropion Xl | Bupropion Hcl | 34 | 13 |
| Cilostazol | Cilostazol | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 12 |
| Linzess | Linaclotide | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 11 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 23 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 21 |
| Budesonide | Budesonide | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Caplyta | Lumateperone Tosylate | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 14 |
| Nitroglycerin Patch | Nitroglycerin | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 13 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | 12 |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Tradjenta | Linagliptin | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Brilinta | Ticagrelor | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 15 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Perphenazine | Perphenazine | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $184.85 · 9 records | PFIZER INC. | ABRYSVO, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, EVENITY, Flector, Kerendia, Licart, PREVNAR 20, Tirosint | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error